2013.04.27,我院孙斐教授研究组在J Cell Physiol上发表题为“MicroRNA-302a sensitizes testicular embryonal carcinoma cells to cisplatin-induced cell death”文章, online

时间:2021-04-12 21:25:02学院:生命科学学院学校:中国科学技术大学

2013.04.27,我院孙斐教授研究组在J Cell Physiol上发表题为“MicroRNA-302a sensitizes testicular embryonal carcinoma cells to cisplatin-induced cell death”文章, online
作者:刘琳、连杰、张慧娟、田卉、梁猛、阴棉棉、孙斐
DOI: 10.1002/jcp.24394
Abstract:
Cisplatin is a commonly used chemotherapeutic agent for the treatment of several human malignancies, such as testicular germ cell tumors (TGCT). The toxic effects persist and those that are present long after chemotherapy affect the overall quality of life of patients. MicroRNAs (miRNAs) play important roles in the responses of cancer cells to chemotherapy and have been shown to modulate cell sensitivity to chemotherapeutic drugs. However, the relationship between miRNA expression and cisplatin sensitivity of TGCT has not been fully explored. In this study, the effects of miR-302a on cisplatin cytotoxicity in TGCT-derived cell line NTERA-2 (NT2) were evaluated. We found that expression levels of miR-302a were increased in cisplatin-treated NT2 cells. Up-regulation of miR-302a significantly increased the sensitivity of NT2 cells to cisplatin by enhancing cisplatin-induced G2/M phase arrest and the subsequent progression to apoptosis. MiR-302a also increased the killing effects of cisplatin by lowering the apoptotic threshold; the same result was also observed in another TGCT-derived cell line, NCCIT. Furthermore, miR-302a-enhanced cisplatin sensitivity was partially mediated through the down-regulation of p21 in NT2 cells. MiR-302a induced apoptosis was further enhanced by silencing of p53 in NT2 cells. p53 levels were inversely associated with the expression of Oct4, Sox2 and Nanog in response to cisplatin. Thus, targeting miR-302a may offer new therapeutic interventions in TGCT.



版权与免责声明:本网页的内容由收集互联网上公开发布的信息整理获得。目的在于传递信息及分享,并不意味着赞同其观点或证实其真实性,也不构成其他建议。仅提供交流平台,不为其版权负责。如涉及侵权,请联系我们及时修改或删除。邮箱:sales@allpeptide.com

返回首页 浙公网安备 33010602009704号;浙ICP备18001318号